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The aim of this study was to characterize Erysipelothrix sp. isolates from clinically affected pigs and their
environment and compare them to the Erysipelothrix sp. vaccines used at the sites. Samples were collected
during swine erysipelas outbreaks in vaccinated pigs in six Midwest United States swine operations from 2007
to 2009. Pig tissue samples were collected from 1 to 3 pigs from each site. Environmental samples (manure,
feed, central-line water, oral fluids, and swabs collected from walls, feed lines, air inlets, exhaust fans, and
nipple drinkers) and live vaccine samples were collected following the isolation of Erysipelothrix spp. from
clinically affected pigs. All Erysipelothrix sp. isolates obtained were further characterized by serotyping.
Selected isolates were further characterized by PCR assays for genotype (E. rhusiopathiae, E. tonsillarum,
Erysipelothrix sp. strain 1, and Erysipelothrix sp. strain 2) and surface protective antigen (spa) type (A, B1, B2,
and C). All 26 isolates obtained from affected pigs were E. rhusiopathiae, specifically, serotypes 1a, 1b, 2, and
21. From environmental samples, 56 isolates were obtained and 52/56 were E. rhusiopathiae (serotypes 1a, 1b,
2, 6, 9, 12, and 21), 3/56 were Erysipelothrix sp. strain 1 (serotypes 13 and untypeable), and one was a novel
species designated Erysipelothrix sp. strain 3 (serotype untypeable). Four of six vaccines used at the sites were
commercially available products and contained live E. rhusiopathiae serotype 1a. Of the remaining two
vaccines, one was an autogenous live vaccine and contained live E. rhusiopathiae serotype 2 and one was a
commercially produced inactivated vaccine and was described by the manufacturer to contain serotype 2
antigen. All E. rhusiopathiae isolates were positive for spaA. All Erysipelothrix sp. strain 1 isolates and the novel
Erysipelothrix sp. strain 3 isolate were negative for all currently known spa types (A, B1, B2, and C). These
results indicate that Erysipelothrix spp. can be isolated from the environment of clinically affected pigs;
however, the identified serotypes in pigs differ from those in the environment at the selected sites. At one of the
six affected sites, the vaccine strain and the isolates from clinically affected pigs were of homologous serotype;
however, vaccinal and clinical isolates were of heterologous serotype at the remaining five sites, suggesting that
reevaluation of vaccine efficacy using recent field strains may be warranted.
Organisms of the genus Erysipelothrix are facultative anaer-
obic small, slender, Gram-positive rods and are distributed
worldwide. Erysipelothrix spp. have been isolated from domes-
tic and wild species of both birds and mammals and have been
identified as the causative agent of the clinical disease known
as “erysipelas” in animals and “erysipeloid” in humans (2). The
genus Erysipelothrix consists of four species and 25 associated
serotypes: E. rhusiopathiae (serotypes 1a, 1b, 2, 4, 5, 6, 8, 9, 11,
12, 15, 16, 17, 19, 21, N), E. tonsillarum (serotypes 3, 7, 10, 14,
20, 22, 23), Erysipelothrix sp. strain 1 (serotype 13), and Erysipe-
lothrix sp. strain 2 (serotype 18) (27, 28). Among the four
species, E. rhusiopathiae causes the greatest economic loss,
primarily to the swine and turkey industries (34, 36).
Three clinical presentations of swine erysipelas are recog-
nized, i.e., acute, subacute, and chronic, and serotypes 1a, 1b,
and 2 are frequently isolated from all disease stages (36). The
additional serotypes (3 to 23 and N) have little clinical signif-
icance in swine. It is estimated that 30 to 50% of healthy pigs
harbor E. rhusiopathiae in tonsils and lymphatic tissue. Sub-
clinically affected pigs are thought to be the source for acute
erysipelas outbreaks due to shedding of the organism in urine,
feces, saliva, and nasal secretions (36).
Economic losses due to swine erysipelas continue to occur
worldwide. For this reason, accurate, reliable, and timely di-
agnostic strategies are important (4). Immunohistochemistry
techniques have been shown to be highly sensitive and specific,
especially when diagnostic specimens include lesions from an-
timicrobial-treated pigs or chronically affected pigs (16). Our
previous studies confirmed that an Erysipelothrix species-selec-
tive broth technique is more sensitive than traditional direct
plating of regular and contaminated specimens (1). Although
the enrichment technique has been used by other countries for
a number of years, it has only recently been adopted by diag-
nostic laboratories within the Midwestern United States (1).
PCR technology is also being employed to complement tradi-
tional detection methods (10, 19, 28, 39). In addition to im-
proved diagnostic assays, methods to further characterize and
differentiate Erysipelothrix spp. through the use of randomly
amplified DNA, pulsed-field gel electrophoresis, and ribotyp-
ing have been shown to be useful and credible (13–15, 17).
* Corresponding author. Mailing address: Veterinary Diagnostic
and Production Animal Medicine, College of Veterinary Medicine,
Iowa State University, Ames, IA 50011. Phone: (515) 294-1137. Fax:
(515) 294-3564. E-mail: tanjaopr@iastate.edu.
 Published ahead of print on 18 August 2010.
1605
Recent investigations have focused on antibodies against the
cell surface components of E. rhusiopathiae and their protec-
tive role. Genes encoding surface protective antigens (Spa)
have been cloned, and nucleotide sequences have been deter-
mined (11, 22). Spa-related genes of all E. rhusiopathiae sero-
types and Erysipelothrix sp. strain 2 (serotype 18) were ana-
lyzed, and Spa proteins can be classified into three molecular
species, SpaA, SpaB, and SpaC (29). The SpaA protein was
identified in E. rhusiopathiae serotypes 1a, 1b, 2, 5, 8, 9, 12, 15,
16, 17, and N, the SpaB protein was identified in E. rhusio-
pathiae serotypes 4, 6, 11, 19, and 21, and the SpaC protein was
identified only in serotype 18 (29). Additional work further
differentiated SpaB into subtypes SpaB1 (serotypes 4, 6, 8, 19,
21) and SpaB2 (serotype 11) (21).
Previous characterization of Erysipelothrix sp. isolates from
affected pigs or isolates from the environment of U.S. swine
sites dates back to the 1970s. The objective of this study was to
identify, characterize, and compare Erysipelothrix sp. isolates
from affected pigs and the environment from erysipelas out-
breaks in six swine operations and to compare those isolates to
the vaccine strains routinely used for vaccination in those same
six operations.
MATERIALS AND METHODS
Site selection. Submissions to the Iowa State University Veterinary Diagnostic
Laboratory (ISU-VDL) between December 2007 and February 2009 from pigs
with a clinical history consistent with acute septicemia (fever, lethargy, skin
lesions, decreased feed intake) or chronic changes (swollen joints, lameness)
suggestive of swine erysipelas were cultured for Erysipelothrix spp. Following a
positive isolation, the submitting veterinarian was contacted to determine the
vaccination status of the herd. Six sites with a vaccination program against E.
rhusiopathiae were identified for environmental sample collection. The six sites
were located in Iowa (sites A to D), Indiana (site E), and Illinois (site F) and
environmental sample collections were done on these sites from 2007 to 2009
within 7 to 14 days of a positive isolation. Samples were collected from the same
barn in pens with additional clinically affected pigs or pens where clinically
affected pigs had been housed recently. The site structures, types, and clinical
signs present are summarized in Table 1. All sites housed pigs in confinement
equipped with automatic feeders and waters.
Pig samples. Sections of spleen, liver, lung, tonsil, kidney, and skin were
collected from clinically affected pigs. A total of 31 samples from 1 to 3 pigs from
each of the six sites were cultured. All isolates obtained were frozen at 80°C for
future evaluation.
Environmental samples. Environmental samples were collected using swabs
(Culturette, Becton Dickinson, Sparks, MD) from the water supply area and
nipple drinkers, wall surfaces, feed lines, air inlets, and exhaust fans. Feed,
manure, and central-line water samples were also collected in sterile 50-ml tubes
(Thermo Fisher Scientific Remel, Lenexa, KS). For purposes of this study, oral
fluid samples were also collected and classified as environmental samples, as they
were from pigs on-site and not from the same pigs from which tissue specimens
were collected. Oral fluids (mainly saliva) were collected only from sites C and
D. In brief, a 3-strand, 1.27-cm-diameter cotton rope was placed in pens with 4
to 6 pigs. The rope was hung at approximately the height of the pigs’ shoulders
and left in place for 20 to 30 min. Oral fluids were then collected by mechanically
compressing the rope and collecting the fluid in sterile 5-ml snap cap tubes (20).
All environmental samples were immediately placed on ice following collection
and stored at 20°C until microbiologic evaluation. Evaluation was done within
3 months of collection.
Vaccine strains. Four attenuated live vaccine strains (sites A, B, D, and E),
one attenuated live autogenous vaccine strain (site F), and one inactivated
vaccine strain (site C) were collected from the respective sites. Attenuated live
vaccines included ERY VAC 100 (Arko Laboratories Limited, Jewell, IA), which
was used at sites A and B; Suvaxyn E-oral (Fort Dodge Animal Health, Inc., Fort
Dodge, IA), which was used at site D; and Ingelvac ERY-ALC (Boehringer
Ingelheim Vetmedica, Inc., St. Joseph, MO), which was used at site E. An
attenuated live autogenous vaccine produced by using a site-specific Erysipelo-
thrix sp. isolate (Newport Laboratories, Worthington, MN) was used at site F. An
inactivated vaccine (Suvaxyn Parvo/E, Fort Dodge Animal Health, Inc., Fort
Dodge, IA), which was serotype 2 based on the manufacturers’ information, was
used at site C. The five attenuated live vaccine strains were immediately placed
on ice following collection and stored at 20°C until evaluation. Evaluation was
done within 3 months of collection.
Bacterial isolation. An Erysipelothrix species-selective broth protocol as pre-
viously described was utilized for bacterial isolation (1). The selective broth was
prepared as follows: 25 g heart infusion broth (Becton Dickinson) was dissolved
in 1 liter of 0.1 phosphate buffer solution (12.02 g of Na2HPO4 and 2.09 g of
KH2PO4 per liter of distilled water) and autoclaved. Sterile fetal bovine serum
(5%; Sigma-Aldrich, St. Louis, MO), kanamycin (400 mg/ml; Sigma-Aldrich),
and neomycin (50 mg/ml; Sigma-Aldrich) were added to the broth (31). Speci-
mens were cultured on an Erysipelothrix species-selective agar as previously
described (18).
Sample preparation. (i) Tissue specimens. Samples were cut into 2- by 3-cm
sections, added to 2 ml of 0.85% physiologic saline solution, and homogenized
using a stomacher (Seward, Bohemia, NY), and 300 l of the resulting tissue
homogenate was added to 3 ml of Erysipelothrix species-selective broth and
incubated at 35°C for 24 to 48 h. At 24 h and again at 48 h, a 100-l subculture
from the Erysipelothrix species-selective broth was put onto a Trypticase soy agar
plate containing 5% sheep blood, a colistin-nalidixic acid (Becton Dickinson)
agar plate containing 5% sheep blood, and an Erysipelothrix-selective plate as
described previously (1). Colonies were subcultured on sheep blood agar plates,
incubated for 24 h, and then biochemically confirmed using standard laboratory
methods (27, 31).
(ii) Water, oral fluids, and vaccines. Each specimen (300 l) was added to 3
ml of Erysipelothrix species-selective broth and incubated.
(iii) Swabs. Culturette swabs were placed directly into the Erysipelothrix spe-
cies-selective broth.
(iv) Manure and feed samples. A portion of the sample (75 to 100 g) was
placed into sterile flasks, and 0.1 M phosphate buffer solution (pH 7.231) was
added for a total volume of approximately 230 ml. The homogenate was mixed
for 10 min with magnetic metal stir bars (37) and then transferred to centrifuge
tubes and centrifuged for 10 min at 1,000 rpm. The supernatant (approximately
2 to 5 ml) was transferred to a flask to which 250 ml of the Erysipelothrix
species-selective broth was added. Each flask was thoroughly mixed, incubated at
35°C for 24 h, and then subcultured to media in a manner similar to that used for
tissue and liquid specimens (37).
Further characterization of the Erysipelothrix sp. isolates. (i) Serotyping. A
pure culture was grown at 37°C for 36 h in 30 ml of heart infusion broth (Becton
Dickinson) supplemented with 10% equine serum (Sigma-Aldrich) (35). The
culture was then killed by adding 1% formalin (Sigma-Aldrich), held at room
temperature for 12 h, harvested by centrifugation, and washed twice in 0.85%
NaCl solution containing 0.5% formalin. Washed cells were suspended in 1.5 ml
of distilled water and autoclaved at 121°C for 1 h (35). The supernatant was
TABLE 1. Characteristics of the six swine operations used in this study
Site Type offacility
Pig
capacity
% of pigs
affected Clinical signs
A Finisher 1,200 3 Rhomboid skin lesions, swollen joints, lethargy
B Finisher 2,200 2 Rhomboid skin lesions, swollen joints, lameness, pyrexia, lethargy
C Breeding herd 1,600 2 Swollen joints, lameness, abortions
D Boar stud 150 1 Rhomboid skin lesions, swollen joints, lameness
E Finisher 2,400 2 Rhomboid skin lesions, lameness
F Breeding herd 1,100 4 Acute death, rhomboid skin lesions, cyanosis of skin, abortions
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collected and used for the agar gel precipitation test (12). Homologous positive
controls were used with each test run. Reactions were recorded after 24 h (35).
(ii) DNA extraction for PCR assays. For DNA extraction, bacterial colonies
were suspended in 200 l of sterile water by vigorous stirring. The suspension
was then used for DNA extraction using the QIAmp DNA blood minikit (Qia-
gen, Valencia, CA) following the manufacturer’s instruction, and the extracted
DNA was kept at 20°C until use.
(iii) Genotype multiplex PCR assay. Further characterization was done on
randomly selected representative isolates of each serotype collected at each site.
A multiplex real-time PCR assay previously described was used to confirm the
presence of E. rhusiopathiae, E. tonsillarum, or Erysipelothrix sp. strain 2 (19). A
modified Erysipelothrix sp. strain 2 primer was utilized to increase the sensitivity
of the assay described by Shen et al. (21).
(iv) Identification of Erysipelothrix sp. strain 1 by conventional PCR assay. A
pair of specific primers, Sp11508F (5-AGACGAAAGCGGCGATTACT-3)
and Sp12362R (5-CCCCTACCACTTGCATTTAATGC-3), were designed
from the 16S rRNA gene of Erysipelothrix sp. strain 1 (GenBank accession no.
AB019249). The PCR was performed in a model 9700 GeneAmp PCR system
(Applied Biosystems, Foster City, CA) in 25-l mixtures containing 1.25 U (0.25
l) Taq DNA polymerase (Invitrogen, Carlsbad, CA), 0.2 mM deoxynucleoside
triphosphate (dNTP), 0.4 M each of the primers, 1.5 mM MgCl2, and 4 l DNA
extract. The cycling conditions were 5 min at 95°C followed by 35 cycles of 40 s
at 95°C, 40 s at 55°C, and 1 min at 72°C and a final extension at 72°C for 7 min.
The amplified PCR products were separated by gel electrophoresis on a 1%
agarose (Amresco, Solon, OH) gel and visualized by UV irradiation after
ethidium bromide staining of the gel. The specificity of the Erysipelothrix sp.
strain 1 conventional PCR assay was investigated by testing E. rhusiopathiae
reference strain Tuzok (serotype 6), E. tonsillarum reference strain Lengyel-P
(serotype 10), Erysipelothrix sp. strain 2 reference strain 715 (serotype 18), and
Erysipelothrix sp. strain 1 reference strain Pe´cs 18 (serotype 13). A specific
product of 855 bp was amplified from the Erysipelothrix sp. strain 1 reference
strain, whereas no PCR products were amplified from the other isolates used.
The sensitivity of this conventional PCR was determined to be 1  104 CFU per
reaction (data not shown).
(v) Spa multiplex real-time PCR. A multiplex real-time PCR assay was utilized
for identification of the Spa type present (spaA, spaB1, spaB2, and spaC) on the
same isolates used for genotyping (21).
(vi) DNA sequencing. From selected samples (of undetermined serotype), the
16S rRNA gene was amplified as described previously (5). Amplified products
were sequenced at the DNA facility of Iowa State University, Ames, IA. The
consensus 16S rRNA sequence was evaluated by comparison with those available
in GenBank using the Basic Local Alignment Search Tool (BLAST).
Nucleotide sequence accession number. Erysipelothrix sp. strain 3 was depos-
ited in GenBank under accession no. HM216182.
RESULTS
Isolation and further characterization of isolates (genotype,
serotype, and spa type). (i) Clinically affected pigs. Among the
pig tissue samples examined, 83.9% (26/31) were found to be
culture positive for Erysipelothrix spp. (see Table 3). Skin sam-
ples were received from all six sites, and 100% (11/11) were
culture positive. Erysipelothrix spp. were also isolated from all
tonsil (5/5) and kidney (3/3) samples obtained; however, these
sample types were not submitted from every site. Table 3
describes the distribution of Erysipelothrix sp. isolates in tissues
submitted from each site. The isolation success was 50% for
heart (1/2) and liver (2/4) tissues and 66.7% for spleen tissues
(4/6). Based on serotyping and multiplex PCR, all 26 isolates
were found to be E. rhusiopathiae. The E. rhusiopathiae isolates
recovered from each site were found to belong to the same sero-
type. The more common serotypes in affected pigs were sero-
types 1a (sites D and F) and 2 (sites A and B). In addition,
serotype 21 was present in pigs from site C, and serotype 1b
was identified in pigs from site E. All 26 E. rhusiopathiae
isolates recovered from pig tissues were positive for spaA.
(ii) Environmental samples. Of 142 environmental samples
examined, 39.4% (56/142) were found to be culture positive for
Erysipelothrix spp. (Table 2). Genotyping and serotyping re-
vealed that 92.9% (52/56) of the environmental isolates be-
longed to E. rhusiopathiae and 5.4% (3/56) belonged to Ery-
sipelothrix sp. strain 1, while in one isolate (1.8%) the genotype
was novel and not previously described. For the purpose of this
study, this genotype was designated Erysipelothrix sp. strain 3
(GenBank accession no. HM216182). The Erysipelothrix sp.
strain 3 isolate was PCR negative for all known genotypes;
however, its 16S rRNA region sequence was identical to
those of GenBank accession no. AB055910.1 and AB055909
(E. rhusiopathiae strain KG-BB2), confirming its Erysipelothrix
sp. origin. The most commonly identified serotype was 1a,
which was identified in 37.5% (21/56) of the isolates, followed
by serotype 2 (33.9% [19/56 isolates]), serotype 1b (10.7%
[6/56 isolates]), serotypes 6 and 21 (each 3.6% [2/56 isolates]),
and serotypes 9, 12, and 13 (each 1.8% [1/56 isolates]). The
serotype of 5.4% (3/56) of the isolates was not determinable.
All environmental isolates identified as E. rhusiopathiae were
found to be positive for spaA, and all isolates identified as
Erysipelothrix sp. strain 1 or with an undeterminable genotype
were negative for spaA, -B1, -B2, and -C. The frequency of
detection of Erysipelothrix spp. in environmental samples is
summarized in Table 2, with nipple drinkers and feed as the
sources where samples had the highest positive isolation rate.
Serotypes that were detected in clinically affected pigs were
also found in manure, feed, wall swabs, central-line water,
nipple drinkers, and fans for serotype 1a; central-line water
and nipple drinkers for serotype 1b; manure, feed, wall swabs,
TABLE 2. Isolation success of Erysipelothrix spp. in different environmental samples and associated genotypes and serotypes
Source of sample
No. of
positive
samples
No. of
negative
samples
% positive
samples Genotype(s) identified Serotypes identified
Manure 13 15 46.4 E. rhusiopathiae, Erysipelothrix sp. strain 1, Erysipelothrix
sp. strain 3a
1a, 2, untypeable
Oral fluid 5 6 45.5 E. rhusiopathiae, Erysipelothrix sp. strain 1 9, 12, 21, untypeable
Feed 9 8 52.9 E. rhusiopathiae 1a, 2
Feed line 0 7 0
Wall 11 12 47.8 E. rhusiopathiae 1a, 2
Central-line water 6 22 21.4 E. rhusiopathiae, Erysipelothrix sp. strain 1 1a, 1b, 6, 13
Nipple drinker 9 8 52.9 E. rhusiopathiae 1a, 1b, 2, 6
Fan 3 8 27.3 E. rhusiopathiae 1a, 2
a Identified as and designated Erysipelothrix sp. strain 3 in the present study.
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central-line water, and fans for serotype 2; and oral fluid for
serotype 21.
(iii) Vaccine strains. All four commercially available atten-
uated live vaccine strains (sites A, B, D, E) were identified as
E. rhusiopathiae serotype 1a, and the autogenous vaccine strain
used on site F was identified as E. rhusiopathiae serotype 2. All
five vaccine strains were positive for spaA.
Isolation success and distribution of isolates from the dif-
ferent sites. (i) Site A. A total of 7 tissue samples from affected
pigs were obtained and 43 environmental samples were col-
lected (Table 3). E. rhusiopathiae serotype 2 was isolated from
5/7 tissues and from 18/43 environmental samples (nipple
drinker swabs, manure, wall swabs, feed, and fan swabs). In
addition, E. rhusiopathiae serotype 1a was identified in 2/5 feed
samples.
(ii) Site B. A total of five tissue samples from affected pigs
were obtained and 39 environmental samples were collected
(Table 3). E. rhusiopathiae serotype 2 was isolated from all
tissue samples and from 1 nipple drinker swab. E. rhusiopathiae
serotype 1a was isolated from 8 environmental samples (cen-
tral-line water, manure, wall swab, and feed). In addition, E.
rhusiopathiae serotype 6 was isolated from a central-line water
sample and a nipple drinker swab, and serotype 13 (Erysipelo-
thrix sp. strain 1) was isolated from a central-line water sample.
(iii) Site C. A total of three tissue samples from affected pigs
were obtained and 31 environmental samples were collected
(Table 3). E. rhusiopathiae serotype 21 was isolated from both
tissue samples and from two oral fluid samples.
(iv) Site D. A total of two tissue samples from affected pigs
were obtained and 12 environmental samples were collected
(Table 3). E. rhusiopathiae serotype 1a was isolated from
both tissue samples but was not identified in any of the
environmental samples collected. Instead, E. rhusiopathiae
serotypes 9 and 12 were isolated from oral fluids and Ery-
sipelothrix sp. strain 1 was isolated from oral fluid and ma-
nure (serotype undeterminable). One additional isolate
(novel Erysipelothrix sp. strain 3; serotype undeterminable)
was isolated from manure.
TABLE 3. Erysipelothrix species isolation and serotypes from clinically affected pigs and environmental samples from six different sites
Site (vaccine
serotype)
Tissue samples Environmental samples
Source
No. of positive
samples/total
no. of
samples
Serotype Source
No. of positive
samples/total
no. of
samples
Serotype
A (1a) Skin 2/2 2 Central-line water 0/6 2
Tonsil 1/1 2 Nipple drinker 2/4 2
Spleen 1/2 2 Manure 7/12 2
Liver 1/2 2 Wall 6/8 2
Feed line 0/4
Feed 3/5 1a (2/3), 2
Fan/inlet 2/4 2
B (1a) Skin 2/2 2 Central-line water 4/9 1a (2/4), 6, 13a
Kidney 1/1 2 Nipple drinker 2/5 2, 6
Spleen 1/1 2 Manure 1/5 1a
Tonsil 1/1 2 Wall 2/8 1a
Feed line 0/3
Feed 3/6 1a
Fan/inlet 0/3
C (2) Skin 1/1 21 Oral fluid 2/4 21
Tonsil 1/1 21 Central-line water 0/9
Spleen 1/1 21 Nipple drinker 0/3
Manure 0/6
Wall 0/3
Feed 0/3
Fan/inlet 0/3
D (1a) Skin 2/2 1a Oral fluid 3/7 9, 12, untypeablea
Central-line water 0/2
Manure 2/2 Untypeablea
Wall 0/1
E (1a) Skin 2/2 1b Central-line water 2/2 1b
Tonsil 2/2 1b Nipple drinker 2/2 1b
Spleen 1/2 1b Feed 2/2 1b
F (2) Skin 2/2 1a Nipple drinker 3/3 1a
Liver 1/2 1a Manure 3/3 1a
Heart 1/2 1a Wall swab 3/3 1a
Kidney 2/2 1a Feed 1/1 1a
Fan/inlet 1/1 1a
a Characterized as a non-E. rhusiopathiae strain.
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(v) Site E. A total of six tissue samples from affected pigs
were obtained and 6 environmental samples were collected
(Table 3). E. rhusiopathiae serotype 1b was isolated from all
tissue and environmental samples.
(vi) Site F. A total of eight tissue samples from affected pigs
were obtained and 11 environmental samples were collected
(Table 3). E. rhusiopathiae serotype 1a was isolated from all
tissue and environmental samples.
DISCUSSION
Results from this investigation indicate that during a clinical
outbreak of swine erysipelas, Erysipelothrix spp. can be isolated
from a variety of environmental samples. Earlier investigations
on swine erysipelas conducted in the United States have re-
ported similar results in identifying Erysipelothrix spp. from
swine and swine production premises; however, studies have
not been conducted on sites with acute swine erysipelas out-
breaks (35, 37). Interestingly, in this study we identified three
Erysipelothrix sp. strain 1 isolates (1/3 was serotype 13 and 2/3
were untypeable), indicating the possibility of one or more new
serotypes within Erysipelothrix sp. strain 1 in addition to sero-
type 13. Moreover, a new genotype of Erysipelothrix designated
Erysipelothrix sp. strain 3, whose serotype and spa type were
also unknown, was identified in an environmental sample, in-
dicating the possibility of a new serotype within the species.
When tissues from affected pigs were investigated, it was
found that skin specimens with visible rhomboid lesions were
consistently culture positive, implicating skin as the tissue of
choice for isolation of Erysipelothrix spp., which is in agreement
with previous work (1). In addition, all tested tonsil samples
(5/5) were found to be culture positive. The existence of Ery-
sipelothrix spp. in the tonsils of healthy pigs is suspected (24);
however, in the current study, all selected isolates obtained
from tonsils had the same serotype as isolates recovered from
other organs of affected pigs. E. rhusiopathiae serotypes 1a, 1b,
and 2 are commonly associated with clinical disease in pigs and
were associated with clinically affected pigs in five of the six
sites. Interestingly, serotype 21 was found in affected pigs from
one of the six sites. While uncommon, this has been reported
previously in a larger study that characterized 1,046 isolates
recovered from pigs with swine erysipelas in Japan and found
that 1.1% of Erysipelothrix sp. isolates belonged to serotype 21
(26). In addition, isolates with reactivity to both serotypes 1b
and 21 (termed 1b  21) have been isolated on four occasions
from affected pigs in three Australian herds with clinical ery-
sipelas (3).
Among the environmental samples, Erysipelothrix spp. were
most frequently isolated in feed and nipple drinkers (both 9/17
samples). This was followed by isolation from wall swabs (11/23
samples) and manure (13/28 samples). While isolation of Ery-
sipelothrix spp. has been described from manure and soil (31),
to our knowledge this is the first description of isolation of
Erysipelothrix spp. from nipple drinkers, walls, and ventilation
fans. Although clinical disease was present at all sites, rela-
tively high percentages of environmental samples were culture
negative (53.5% at site A, 69.2% at site B, 93.5% at site C, and
41.7% at site D). This may have to do with the total number of
samples collected, the sample types, storage, or a delay be-
tween the original case submission and follow-up site visit or
may be related to shedding mechanisms of Erysipelothrix spp.
Previous studies demonstrated no evidence of growth or main-
tenance of Erysipelothrix spp. in soil or manure samples from
swine pens (32), but the role of soil, manure, and pit slurry as
reservoirs or sources of infection is not completely understood
(34).
The attenuated live vaccine strains utilized on the different
sites were also collected, cultured, and characterized. All sites
in this investigation utilized a vaccine as part of an erysipelas
control plan. Four of six sites (sites A, B, D, and E) utilized
attenuated live vaccines, produced by three manufacturers. All
three of these commercially available vaccines were found to
be positive for E. rhusiopathiae serotype 1a. Interestingly, two
of the four sites using these vaccines had clinical infections
with serotype 2, one of the four sites had infections with sero-
type 1b, and one site had infections with serotype 1a based on
the isolation of these serotypes from affected pigs. One site (F)
used an autogenous attenuated live vaccine based on a site-
specific isolate. The isolate recovered from the autogenous
vaccine was identified as serotype 2; however, E. rhusiopathiae
serotype 1a was isolated from affected pigs from this site and
was also the only serotype present in the environment. Many
factors affect the ability of a live vaccine to elicit protection,
including but not limited to vaccine storage, route and dose of
administration, age, maternal immunity, antimicrobial therapy,
and the vaccine strains used. Based on cross-protection studies
done in the 1980s, it was found that live serotype 1a protected
against serotypes 1b and 2 (25). At site D, we found that the
serotype of the live vaccine used was identical to that isolated
from the pig tissues. In Japan in 1932, an acriflavine-resistant
attenuated live vaccine was developed; this vaccine has been
used intensively since the erysipelas outbreaks in 1966 and
1967. However, since the 1990s, approximately 2,000 pigs an-
nually have been shown to have acute and subacute septicemia.
It is believed that the live vaccine was the causal agent for this
high number of pigs with swine erysipelas (6), and this could
also be a possibility in herd D. Earlier studies have shown that
serotype 2 bacterins can protect against serotype 1 challenge
(33, 38). Cross-protection was apparently not sufficient to pre-
vent clinical disease in this case, providing evidence of the need
to further evaluate cross-protection in the swine model using
recent field isolates.
In this study, Erysipelothrix spp. were isolated from the en-
vironments of clinically affected swine. In addition, the Erysip-
elothrix sp. isolates recovered from clinically affected pigs and
the majority of the Erysipelothrix sp. isolates recovered from
the pigs’ environments were found to be identical in four of the
six sites (site A, serotype 2; site C, serotype 21; site E, serotype
1b; and site F, serotype 1a; Table 3). However, dissimilarities
between isolates in pigs and isolates from their environments
were identified in two of the six sites investigated. While pigs in
these two sites were infected with very common serotypes
(serotypes 1a and 2), a variety of serotypes were identified in
the environment (serotypes 1a, 2, 6, 9, 12, 13, and untypeable)
(Table 3). It has been determined that E. rhusiopathiae sero-
types remain stable through swine serial passage or under
different storage conditions (23, 30). In this investigation, se-
rotypes identified in the environment were both identical to
(4/6 sites) and different from (2/6 sites) what was isolated from
clinically affected pigs from these sites; however, affected sites
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were visited only once. To fully understand the interactions
and relations between isolates associated with disease in pigs
and isolates present in the environment, repeated collection
over time of samples would provide more complete informa-
tion.
In this study, all recovered isolates were also tested for their
dominant spa type. The Spa protein of E. rhusiopathiae has
been shown to be attached at the cell surface level of the
bacteria and also to be a major protective antigen against
infection by E. rhusiopathiae (7, 8, 11, 29). All E. rhusiopathiae
isolates obtained from affected pig tissues (serotypes 1a, 2, and
21), environmental samples (serotypes 1a, 1b, 2, 6, 9, 12, and
21), and vaccine strains (serotypes 1a and 2) were found to
contain a single spa type, spaA. The identification of spaA in
serotype 21 is in contrast to a previous report where spaB was
identified (29) but in agreement with another study which
reported serotype 21 as expressing SpaA (9). Moreover, the
findings of this study support previous results that spaA is
highly conserved in serotypes most often associated with clin-
ical swine erysipelas (9). All five vaccine strains characterized
were found to be positive for spaA, and based on the current
state of knowledge, cross-protection should have occurred (9,
29). However, the role of vaccine handling, administration, and
timing should not be overlooked and can be considered a
potential explanation for the lack of protection. In addition,
vaccine efficacy testing of vaccine batches may be unreliable, as
testing is often done in mice, in which vaccine efficacy may or
may not mimic what occurs in pigs. All three Erysipelothrix sp.
strain 1 isolates and the Erysipelothrix sp. strain 3 isolate were
found to be negative for all spa types investigated (A, B1, B2,
C). These isolates were identified in two sites and were present
in central-line water, oral fluid, and manure. No recent reports
have implicated Erysipelothrix sp. strain 1 to be pathogenic.
Moreover, as this strain was not isolated from pig tissue based
on present evidence, it is unlikely that Erysipelothrix sp. strain
1 is an important pathogen.
Much interest has recently been generated regarding spa
types. Results of this study agree with previous work and in-
dicate that spa types are likely to be quite conserved among
swine isolates of Erysipelothrix spp. associated with disease.
However, all of the isolates obtained from clinically affected
pigs were E. rhusiopathiae strains, which are known to contain
only either spaA or spaB. In this study, spaA was the only type
found, which is consistent with findings of others who have
reported that serotypes 1a, 1b, and 2 (all spaA) predominate in
clinically affected pigs. What is interesting is that the serotype
21 isolate from pig tissue from site C contained spaA and not
spaB as previously described (29). In one investigation in Aus-
tralia, four farms were found to have isolates that were reactive
to both 1b and 21 (3), which could indicate a possible reason
for why spaA was found in this case.
Data from acute swine erysipelas outbreaks investigated in
this study indicate that during an acute outbreak situation,
Erysipelothrix spp. can be isolated from both clinically affected
pigs and their environments. Characterization of the Erysipe-
lothrix sp. isolates using serotyping and genotyping assays in-
dicated that isolates from affected pigs and the environment
are not necessarily the same on individual sites.
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